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Ferritin in decompensated cirrhosis: Iron or inﬂammation?
As hepatic synthetic dysfunction progresses in end stage liver
disease, reduced production of hepcidin, the liver-derived iron
regulatory hormonemay occur [7,8]. Hepcidinmay be further sup-
pressed by oxidative stress, which is prevalent in decompensated
cirrhosis [9,10]. Deﬁcient hepcidin production leads to elevated
iron absorption, hyperferritinaemia and hepatic iron deposition,
which would exacerbate the original insult. No comment is made
on the potential value of serum hepcidin measurements in these
patients. Furthermore, the authors do not provide transferrin sat-
uration levels, which, if raised, would indicate iron overload as a
contributing factor.
In summary, whileMaiwall and colleagues provide an interest-
ing addition to the predictors of outcome in patients with decom-
pensated cirrhosis, further information would be of value in order
to guide therapeutic strategies and future research in this area.
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JOURNAL OF HEPATOLOGYTo the Editor:
In a recent article, Maiwall and colleagues describe serum ferritin
as a predictor of mortality in patients with decompensated cirrho-
sis. The authors conclude that the association between elevated
serum ferritin and mortality may have therapeutic implications
[1].
Elevated serum ferritin is commonly seen in many causes of
chronic liver disease and is thought to relate to hepatic iron over-
load or inﬂammation, or a combination of both. Indeed, in the
absence of systemic inﬂammation, serum ferritin is an excellent
marker of body iron stores, such as is seen in hereditary haemo-
chromatosis, a frequent cause of hepatic iron excess [2]. Alcoholic
and non-alcoholic fatty liver disease and chronic viral hepatitis
are associated with hepatic inﬂammation and mild to moderate
hepatic iron accumulation, making serum ferritin less interpret-
able. Distinguishing the cause of hyperferritinaemia is an often
encountered clinical issue.
Although it has been widely accepted that damaged hepato-
cytes are the main source of circulating ferritin, Cohen et al.
recently revealed that a major contribution occurs from macro-
phages [3]. In the context of decompensated cirrhosis and acute-
on-chronic liver failure, where the importance of macrophage
activation is well recognized [4], this ﬁnding is of relevance. The
addition of C-reactive protein (CRP) measurement in this study
would help to clarify the driver of hyperferritinaemia, indeed
CRP has been shown to predict short-term survival in patients
with cirrhosis and acute-on-chronic liver failure [5,6].Journal of Hepatology 2015 vol. 62 j 492–501 499
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Letters to the Editor
500Reply to: ‘‘Ferritin in decompensated cirrhosis: Iron
or inﬂammation?’’To the Editor:
We would like to thank Ryan et al. for taking keen interest in our
recently published manuscript wherein we show that serum fer-
ritin is a predictor of early mortality in patients with decompen-
sated cirrhosis (DC) [1]. We completely agree with their
comments that serum ferritin in patients with DC is a marker
of both inﬂammation and iron overload. Ferritin is an established
marker of secondary iron overload in these patients. We in our
study, therefore excluded patients with secondary iron overload
to demonstrate the role of ferritin primarily as a marker of sys-
temic inﬂammation and macrophage activation in the absence
of iron overload. We looked at the correlation of ferritin with
leucocyte counts (TLC) to elucidate its role as a marker of sys-
temic inﬂammation. In the CANONIC study both leucocytosis
and C-reactive protein (CRP) were shown as markers of the sys-
temic inﬂammatory response syndrome [2]. Of these, the utility
of adding leucocyte counts and not CRP was also proposed in a
new prognostic score for patients with cirrhosis and liver failure
[3]. We do not routinely measure CRP levels in our patients and
therefore the association of ferritin with CRP could not be deter-
mined and was not shown in this study. As expected, serum
ferritin also correlated with markers of iron overload i.e. serum
iron (p <0.001, r = 0.33), TIBC (p <0.001, r = 0.64) and transferrin
saturation (TS) (p <0.0001, r = 0.58).
Because we had excluded patients with secondary iron over-
load in this study, obviously raising a potential for selection bias,
we also looked at serum ferritin in a separate cohort of DC, irre-
spective of the iron overload state (n = 377, 77% males). Here,
again we explored the relationship of ferritin with TLC (as a mar-
ker of inﬂammation) and transferrin saturation (TS) (as a marker
of iron overload). Log transformation of ferritin, TS and TLC was
done for analysis. Interestingly, a signiﬁcant and direct linear
association was noted between serum ferritin and TLC
(r2 = 0.71, p <0.0001,) as well as TS (r2 = 0.96, p <0.0001,)
(Fig. 1A and B). However, this relationship was stronger for TS
as compared to TLC (Fig. 1B). Ferritin levels were maximally ele-
vated for patients with both high TS and TLC (Fig. 1C). On univar-
iate analysis ferritin (Fig. 1D), TLC and TS were signiﬁcantly
associated with mortality. On multivariate analysis (after exclud-
ing ferritin), both TLC (HR 1.53, 95% CI 1.01–2.48) and TS (HR 1.8,
95% CI 1.02–3.1) signiﬁcantly predicted mortality, highlighting
the prognostic signiﬁcance of both systemic inﬂammation and
iron overload in patients with DC. Also, ferritin as a single bio-
marker could reﬂect both inﬂammation and iron overload in
these patients.
Serum hepcidin is inﬂuenced both by inﬂammation and iron
overload and a positive correlation of hepcidin with ferritin and
TS has been reported in patients with cirrhosis [4,5]. We have
already reported a decrease in serum hepcidin along with
increased serum iron and ferritin in patients with ACLF as com-
pared to cirrhosis and healthy controls. The levels also correlated
with the severity of the disease [4]. Hepcidin is synthesized in
hepatocytes, and in states of iron excess it maintains iron homeo-
stasis by preventing iron absorption from the gut and its release
by macrophages. Therefore, reduced levels of hepcidin in patients
with severe liver disease perpetuate the state of iron overload.
However, as stated by Ryan et al. we could not unveil the role
of hepcidin in this study as it was a retrospective study. Because
excess iron is toxic as it potentiates oxidative stress, removal of
excess iron could be beneﬁcial, however, future prospective stud-
ies are needed to provide deﬁnite answers to these interesting
observations.Journal of Hepatology 2015 vol. 62 j 492–501
